Real-world evidence for the use of olaparib in pancreatic cancer in Spanish hospitals
{{output}}
Patients with pancreatic cancer (PC) harboring DNA damage repair genes (DDRg) alterations, particularly BRCA1/2, may benefit from olaparib. Although the phase III POLO trial demonstrated improved progression-free survival (PFS) with olaparib as maintenance the... ...
